Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:depression
|
| gptkbp:approves |
gptkb:2008
gptkb:FDA |
| gptkbp:atccode |
N06 AX16
|
| gptkbp:available_on |
gptkb:tablet
|
| gptkbp:brand |
gptkb:Pristiq
|
| gptkbp:category |
gptkb:C
|
| gptkbp:chemical_formula |
C16 H25 N
|
| gptkbp:class |
serotonin-norepinephrine reuptake inhibitor (SNRI)
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
MAO inhibitors
severe renal impairment hypersensitivity to desvenlafaxine |
| gptkbp:defines |
gptkb:O-desmethylvenlafaxine
|
| gptkbp:developed_by |
gptkb:Wyeth_Pharmaceuticals
|
| gptkbp:dosage_form |
extended-release tablet
50 mg once daily |
| gptkbp:duration |
at least 6 weeks
|
| gptkbp:financials |
DB06280
|
| gptkbp:formulation |
oral solution
extended-release capsule |
| https://www.w3.org/2000/01/rdf-schema#label |
Desvenlafaxine
|
| gptkbp:indication |
anxiety disorders
social anxiety disorder panic disorder |
| gptkbp:interacts_with |
gptkb:beer
other antidepressants |
| gptkbp:is_monitored_by |
blood pressure
renal function liver function |
| gptkbp:legal_status |
prescription only
|
| gptkbp:lifespan |
11 hours
|
| gptkbp:mechanism_of_action |
inhibits reuptake of serotonin and norepinephrine
|
| gptkbp:metabolism |
liver
|
| gptkbp:pharmacokinetics |
bioavailability 80%
dose-dependent increase in norepinephrine dose-dependent increase in serotonin |
| gptkbp:rounds |
urine
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:side_effect |
dizziness
nausea constipation dry mouth sweating suicidal thoughts increased blood pressure serotonin syndrome |
| gptkbp:structure |
phenethylamine derivative
|
| gptkbp:symptoms |
dizziness
fatigue nausea irritability |
| gptkbp:trade |
Khedezla
|
| gptkbp:used_for |
major depressive disorder
|
| gptkbp:bfsParent |
gptkb:Searle_Pharmaceuticals
|
| gptkbp:bfsLayer |
5
|